![\"\"](\"https:\/\/opeo.consulting\/wp-content\/uploads\/2026\/02\/image0-1024x576.png\")
<\/p>\n<\/p>\n
Health sovereignty has become a central topic in the European debate. Relocation announcements are multiplying, industrial strategies are being redesigned, and the need to secure supply chains is no longer disputed by anyone.<\/p>\n
Yet beyond political decisions and geopolitical shifts, a more structural question remains largely underestimated: is Europe today organized to produce its medicines in a sufficiently competitive and efficient way in a global environment that has become considerably more demanding?<\/p>\n
The rise of China and India in generics and active pharmaceutical ingredients, the growing weight of the U.S. market in the economic balance of major pharmaceutical companies, as well as the assertive industrial policies implemented across the Atlantic, are profoundly reshaping the geography of the sector. In this context, every operational performance factor becomes strategic.<\/p>\n
And part of the European challenge lies within the industrial sites themselves.<\/p>\n
The European pharmaceutical industry operates within one of the most demanding regulatory frameworks in the world.<\/p>\n
This requirement is fully legitimate: it protects patients, secures treatments, and guarantees the traceability of healthcare products.<\/p>\n
But it has profoundly transformed the nature of industrial operations.<\/p>\n
An increasing share of site activity is now devoted not strictly to producing, but to documenting, verifying, analyzing, and demonstrating compliance. This reality is often described as the Hidden Factory<\/em>: invisible industrial capacity absorbed by deviation management, OOS\/OOT investigations, re-analyses, documentation reviews, and batch release processes.<\/p>\n In some environments, this \u201chidden factory\u201d can represent up to one third \u2014 or even more \u2014 of the mobilized capacity. On the ground, this translates very concretely: operators devote a significant portion of their time to documentation, laboratories see a substantial share of their workload absorbed by administrative tasks, and quality assurance teams are largely mobilized by event management and dossier review.<\/p>\n Quality no longer merely frames production. It now fundamentally structures industrial performance.<\/p>\n Europe still has considerable strengths: recognized scientific expertise, strong capabilities in innovative medicines, and high quality standards that constitute a competitive advantage in terms of trust and reputation.<\/p>\n At the same time, however, organizations have gradually accumulated layers of successive controls and validations, often added following audits, regulatory observations, or cautious interpretations of requirements. This dynamic, sometimes referred to as defensive compliance or \u201cgold plating,\u201d follows an understandable logic: in a sector where health risk is critical, doing too little always appears more dangerous than doing too much.<\/p>\n However, this accumulation comes at a cost.<\/p>\n It mobilizes expert resources, lengthens release timelines, complicates flows, and rigidifies organizations. In a global environment where investment trade-offs are increasingly sensitive to operating conditions, this complexity becomes a competitiveness factor in its own right.<\/p>\n Faced with this growing complexity, manufacturers have heavily invested in process digitalization: deployment of electronic batch records, integration of quality systems, automation of traceability, and improvement of data reliability.<\/p>\n These transformations have delivered tangible results. In particular, they help reduce errors linked to manual transcription, accelerate reviews, and implement \u201creview by exception\u201d mechanisms, focusing teams\u2019 attention on significant deviations rather than on the exhaustive validation of compliant processes. Nevertheless, one point deserves to be clearly emphasized: digitalization improves the execution of existing processes, but it does not necessarily question their intrinsic relevance. Digitizing a complex process does not automatically make it simpler. If controls are redundant or oversized from the outset, technology risks freezing complexity instead of reducing it.<\/p>\n The main lever for transformation therefore cannot be purely technological.<\/p>\n The real challenge is operational and organizational. It consists of returning to fundamentals: identifying controls that are truly critical for patient safety and process robustness, eliminating redundancies, clarifying responsibilities, and harmonizing practices across sites.<\/p>\n In other words, moving from primarily defensive compliance to intentional compliance.<\/p>\n Intentional compliance does not mean lowering standards. On the contrary, it requires a finer understanding of risks, better use of data from quality management systems (QMS), and the ability to objectify decisions. Why is the same incident categorized differently from one site to another? Why do certain documentation flows mobilize so many resources without creating additional value in terms of safety?<\/p>\n Today, data makes it possible to analyze these gaps, reduce variability, and focus teams\u2019 energy where it truly matters: on root cause control and operational reliability.<\/p>\n Industrial investments and political decisions will be decisive for the future of the European pharmaceutical industry. But they will not be sufficient on their own.<\/p>\n Freeing existing capacity is an equally strategic lever. Simplifying quality flows, accelerating review processes, reducing the Hidden Factory, and harmonizing practices can recover a significant share of operational performance \u2014 without any compromise on patient safety.<\/p>\n In an environment where the United States is massively attracting capital and China is rapidly moving up the value chain, Europe cannot afford to be structurally heavier to operate.<\/p>\n The question is not about doing less quality.<\/p>\n The question is about delivering smarter quality \u2014 more targeted, more coherent with contemporary industrial challenges.<\/p>\n Producing medicines or producing controls?<\/p>\n The debate does not oppose these two realities. It invites us to reconcile them.<\/p>\n Because European health sovereignty will be decided as much in macroeconomic trade-offs as in the ability of sites to fundamentally transform their operational model.<\/p>\n An in-depth analysis to understand how to concretely transform this silent challenge into a lever for sustainable competitiveness.<\/p>\nA European Paradox<\/strong><\/h2>\n
Digitalization: A Powerful Lever, but Not Sufficient<\/strong><\/h2>\n
Toward More Intentional Quality<\/strong><\/h2>\n
Sovereignty Begins in Processes<\/strong><\/h2>\n
Watch the full discussion in video.<\/h2>\n